3Friedenberg F,Jensen G,Gujral N,et al.Serumalbuminispredictive of 30 daysurvival after percutaneousen doscopicgastrostomy[J].JPEN,1997,21:72-74.
4Park,Williams D P,Naisbitt D J,et al.Investigation otoxicmetabo litesdufing drugdev elopment[J].Toxicologand Applied Pharmacology,2005,207 (2Suppl):S425.
5Zollner G,Trauner M.Molecular pathogenesis of cholestasis[J].Wien Med Wochenschr,2006,156(13 214):380.
6Li A P.Areview of the commonproperties of drugs with idio-syncratichepa to toxicity and the/multipledeterminanthy-pothesis for themanifestation of idiosyncratic drugtoxicity[J].Chemico 2 Biological Interactions,2002,142(122):7.
8Andrade R J,Lucena M I,Alonso A,et al.HLAclassgen -otype in fluences the type of Ii Verinjuryindrug-inducedidio -syncraticliverdisease[J].Hepatology,2004,39(6):1603.
9Schnyder B,Burkhart C,Schnyder F K,et al.Recognition of sulfamethoxazoleandits reactivemetabolitesbydrug-specific CD4 + Tcellsfromaller gicindividuals[J].JImmunol,2000,164 (12):6647.
10Ju C,Reilly T P,Bourdi M,et al.Protectiverole of Kupffercell sinacetaminophen-in ducedhepatie in juryinmice[J].Chem Res Toxicol,2002,15(12):1504.
